Safety study of a test oral iron chelator in male iron-overloaded patients

Phase 1

Completed

• Conditions: Iron overload in transfusion-dependent patients; Blood - Other blood disorders; Blood - Haematological diseases

• Registration Number: ACTRN12609000213246
• Lead Sponsor: FerroKin BioSciences Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-04-27
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 4

Inclusion Criteria

Trasnfusion-dependent patients wo have transfusional overload, requiring chronic treatment with deferoxamine, deferasirox or deferiprone. Patients must be willing to discontinue all existing iron chelation therapies for a minimum of seven days prior to admission to clinic.

Exclusion Criteria

Received or is anticipated to receive a new prescription systemic or topical medication within 14 days of study start, or over-the-counter medications within 48 hours. Any condition that would interfere with drug absorption (ie chronic diarrhoea).

Study & Design

• Study Type: Interventional
• Study Design: Not specified